Healthcare
Live Price
Offline$1.24
+0.00% today
1Y Change
-32.97%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The United Laboratories International Holdings Limited (ULIHF) is a Healthcare stock with a market cap of $16.31B and listed on OTC. The stock last traded around $1.24 and down 33.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -6.5%, EPS growth of -28.1%, a dividend yield of 6.0%. What stands out right now is revenue -6.5%, EPS -28.1%, free cash flow -35.6% with operating margin 17.3% and ROIC 8.1%. The dividend matters to the case here, with a current yield around 6.0%. Valuation is more restrained than many high-expectation growth names at P/E 11.9 and price/sales 1.2. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ULIHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ULIHF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ULIHF Max Drawdown
-47.81%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ULIHF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$9.7B
-14.4% YoY
FY Net Income
$988.1M
-37.5% YoY
Free Cash Flow
$1.0B
-2.2% YoY
Revenue Growth
-6.5%
EPS Growth
-28.1%
Gross Margin
41.8%
Net Margin
15.9%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12.9B | 13.8B | 13.7B | 11.3B | 9.7B |
| Gross Profit | 5.4B | 6.1B | 6.3B | 5.0B | 4.2B |
| Operating Income | 2.2B | 3.1B | 3.3B | 2.0B | 1.4B |
| EBITDA | 2.8B | 3.9B | 4.0B | 2.5B | 2.0B |
| Net Income | 2.0B | 2.7B | 2.7B | 1.6B | 988M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.2B | 6.3B | 4.3B | 4.7B | 3.3B |
| Total Assets | 30.9B | 25.8B | 21.0B | 19.0B | 16.3B |
| Total Liabilities | 13.3B | 11.4B | 8.3B | 8.4B | 7.0B |
| Shareholder Equity | 17.4B | 14.4B | 12.7B | 10.6B | 9.3B |
| Total Debt | 5.0B | 3.2B | 1.5B | 2.5B | 1.8B |
| Net Debt | -6.2B | -3.2B | -2.8B | -2.3B | -1.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.6B
+1.6% YoY
Capital Expenditures
531M
-10.1% YoY
Free Cash Flow
1.0B
-2.2% YoY
Key ratios
Gross Margin
41.8%
Operating Margin
17.3%
Net Margin
15.9%
ROE
12.6%
Debt / Equity
0.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.